Investigational drug · Phase 2
HT-101
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis B, Chronic Hepatitis B Virus Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "HT-101"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HT-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B
- Chronic Hepatitis B Virus Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "HT-101" as an intervention, largest first.
- A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07917910 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 30, 2028
Drug: HT-101 + HT-102; HT-101 placebo + HT-102 placebo · For: Chronic Hepatitis B Virus Infection
- A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07183306 · 86 participants · Start Dec 30, 2024 · Primary completion Aug 24, 2027
Drug: HT-101; HT-102 · For: Chronic Hepatitis B
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 7 sites in all
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT06746311 · 82 participants · Start Nov 22, 2022 · Primary completion May 13, 2024
Drug: HT-101; HT-101 and 1 more · For: Chronic Hepatitis b
Sites: Beijing, China; Guangzhou, China; Xuzhou, China · 7 sites in all
- A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07245953 · 60 participants (planned) · Start Nov 5, 2025 · Primary completion Feb 2027
Drug: HT-101; HT-102 and 2 more · For: Chronic Hepatitis B
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-101, an RNAi Therapeutic Targeting HBV Infection.
Zhang J, Li J, Wu L, et al. · Clin Pharmacol Drug Dev 2025
- Inhibition of Hepatitis B Virus Replication by a Novel GalNAc-siRNA In Vivo and In Vitro.
Zhang Z, Ma Y, He Y, et al. · ACS Omega 2025
Also in development for Chronic Hepatitis B
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- NAsNucleoside analogs, acidPhase 23 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis B, HBV Infection With LLV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.